Compare NPK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | CGEM |
|---|---|---|
| Founded | 1905 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | NPK | CGEM |
|---|---|---|
| Price | $122.90 | $11.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.13 |
| AVG Volume (30 Days) | 73.4K | ★ 707.4K |
| Earning Date | 03-13-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $474,243,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.96 | ★ N/A |
| Revenue Growth | ★ 34.75 | N/A |
| 52 Week Low | $77.63 | $5.68 |
| 52 Week High | $125.04 | $13.33 |
| Indicator | NPK | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 57.77 |
| Support Level | $119.66 | $11.53 |
| Resistance Level | $123.75 | $12.99 |
| Average True Range (ATR) | 3.32 | 0.76 |
| MACD | 0.20 | 0.12 |
| Stochastic Oscillator | 78.41 | 61.36 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.